Search results
Emcure Pharmaceuticals IPO last bidding date today. Should you subscribe? Check GMP, subscription...
Livemint· 13 hours agoEmcure Pharmaceuticals IPO aims to utilise funds to reduce long-term debt and focus on important...
Actress Bhavana Ramanna Shares Her Unique Experience Of Rearing Cow In Bengaluru - News18
News18· 2 days agoBhavana Ramanna is a popular actress in the Kannada film industry who has been a part of some of the...
Faceless perpetrators make online space unsafe for women
The Hindu· 16 hours agoThe murder of a fan of Kannada actor Darshan has sent shock waves across not just Karnataka but...
Emcure Pharmaceuticals IPO opens today: GMP, subscription status, review, other details. Apply or...
Livemint· 3 days agoEmcure Pharmaceuticals IPO subscription opens with ₹582 crore raised from anchor investors. Price...
Game of cricket
Indiatimes· 7 days agoThe cricket tournament is scheduled for July 20 and 21. “I am very happy to be part of the team that is organising a cricket tournament for artists and...
Queens Premier League: Sandalwood Heroines to Showcase Cricket Talent
Indiatimes· 17 hours agoused to be brand ambassadors for cricket tournaments and only got a chance to clap and cheer in the...
Shark Tank Judge Namita Thapar To Earn Rs 127 Crore From Emcure IPO
NDTV· 2 days agoNamita Thapar, the Executive Director of Emcure Pharmaceuticals, is set to earn approximately Rs...
Emcure Pharmaceuticals IPO: Issue booked 4.98 times on the second bidding day. Check latest GMP,...
Livemint· 1 day agoEmcure Pharmaceuticals IPO subscription status: Emcure Pharmaceuticals, backed by Bain Capital,...
Emcure Pharmaceuticals IPO Day 2: From key risks to financials, here are 10 things to know from RHP...
Livemint· 1 day agoEmcure Pharmaceuticals IPO saw positive investor response with overwhelming demand, offering new...
Emcure Pharma IPO to open on July 3, Shark Namita Thapar likely to earn ₹127 crore - CNBC TV18
CNBC TV18· 3 days agoThe initial share sale of Pune-based Emcure Pharmaceuticals will open for public subscription on...